Trading Halt
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Imugene Limited has requested a trading halt for its securities pending an announcement regarding a proposed capital raising. The halt will remain in effect until the earlier of the announcement's release or the commencement of normal trading on a specified date.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-halt-466
In the deck
Earlier from Imugene
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- FDA Supports Strategy Toward Registration for Azer-cel
- Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
- Strategic Collaboration with JW Therapeutics
Later from Imugene
- 100% and 80% ORRs in Subset Indications in azer-cel study
- $20M placement and SPP, convertible notes amended
- Prospectus
- Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)
- Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene